Ensysce Biosciences, Inc. (ENSC)
NasdaqCM
Fundamentals
Valuation and ratings
Ensysce Biosciences, Inc. trades at USD0.26. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Super investor ownership
1 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$30.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own ENSC?
1 of the institutions we track reported a position in ENSC in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for ENSC, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.